DNA binding ligands targeting drug-resistant Gram-positive bacteria. Part 1: Internal benzimidazole derivatives

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 5, 2004, Pages 1253-1257

  Bürli, Roland W ^a   McMinn, Dustin ^a   Kaizerman, Jacob A ^a   Hu, Wenhao ^a   Ge, Yigong ^a   Pack, Quinn ^a   Jiang, Vernon ^a   Gross, Matthew ^a   Garcia, Martin ^a   Tanaka, Richard ^a   Moser, Heinz E ^a  

^a Genesoft Pharmaceuticals Inc   (United States)

Author keywords

Antibiotics; DNA binders; Lead optimization; Minor groove

Indexed keywords

AMIDE; ANTIBIOTIC AGENT; PENICILLIN G; PYRROLE DERIVATIVE; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL PERITONITIS; CONTROLLED STUDY; DNA BINDING; DRUG POTENCY; DRUG TARGETING; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; GRAM POSITIVE BACTERIUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOUSE; NONHUMAN; PENICILLIN RESISTANCE; SEPSIS; STREPTOCOCCUS PNEUMONIAE;

BACTERIA (MICROORGANISMS); ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEGIBACTERIA; POSIBACTERIA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 10744227234     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.12.042     Document Type: Article

References (29)

1. Projan S.J., Youngman P.J. Curr. Opin. Microbiology. 5:2002;463.
2. McDevitt D., Rosenberg M. TRENDS in Microbiology. 9:2001;611.
3. Projan S.J. Curr. Opin. Pharmacology. 2:2002;513.
4. Brands M., Grande Y.C., Endermann R., Gahlmann R., Krüger Raddatz S. Bioorg. Med. Chem. Lett. 13:2003;2641.
5. Raju B., Mortell K., Anandan S., O'Dowd H., Gao H., Gomez M., Hackbarth C., Wu C., Wang W., Yuan Z., White R., Trias J., Patel D. Bioorg. Med. Chem. Lett. 13:2003;2413.
6. Kiho T., Nakayama M., Yasuda K., Miyakoshi S., Inukai M., Kogen H. Bioorg. Med. Chem. Lett. 13:2003;2315.
7. Laursen J.B., de Visser P.C., Nielsen H.K., Jensen K.J., Nielsen J. Bioorg. Med. Chem. Lett. 12:2002;171.
8. Arcamone F., Penco S., Orezzi P., Nicolella V., Pirelli A. Nature. 203:1964;1064.
9. Dervan P.B., Edelson B.S. Curr. Opin. Struct. Biol. 13:2003;1.
10. Sharma S.K., Reddy B.S.N., Lown J.W. Drugs Future. 26:2001;39.
11. Boger D.L., Fink B.E., Hedrick M.P. J. Am. Chem. Soc. 122:2000;6382.
12. Bürli R.W., Ge Y., White S., Baird E.E., Touami S.M., Taylor M., Kaizerman J.A., Moser H.E. Bioorg. Med. Chem. Lett. 12:2002;2591.
13. Ge Y., Difuntorum S., Touami S., Critchley I., Bürli R., Jiang V., Drazan K., Moser H. Antimicrob. Agents Chemother. 46:2002;3168.
14. Kaizerman J.A., Gross M.I., Ge Y., White S., Hu W., Duan J.X., Baird E.E., Johnson K.W., Tanaka R.D., Moser H.E., Bürli R.W. J. Med. Chem. 46:2003;3914.
15. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Adv. Drug Delivery Rev. 23:1997;3.
16. Pjura P.E., Grzeskowiak K., Dickerson R.E. J. Mol. Biol. 197:1987;257.
17. Minehan T.G., Gottwald K., Dervan P.B. Helv. Chim. Acta. 83:2000;2197.
18. Tawar U., Jain A.K., Dwarakanath B.S., Chandra R., Singh Y., Chaudhury N.K., Khaitan D., Tandon V. J. Med. Chem. 46:2003;3785.
19. Briehn C.A., Weyermann P., Dervan P.B. Chem. Eur. J. 9:2003;2110.
20. Renneberg D., Dervan P.B. J. Am. Chem. Soc. 125:2003;5707.
21. Kumar S., Yadagiri B., Zimmermann J., Pon R.T., Lown J.W. J. Biomol. Struct. Dyn. 8:1990;331.
22. Stock T., Steen H.B. J. Histochem. Cytochem. 33:1985;333.
23. 2O), and dried to give dimer 6 (1.18 g, 90%).
24. Baird E.E., Dervan P.B. J. Am. Chem. Soc. 118:1996;6141.
25. Yamamoto Y., Kimachi T., Kanaoka Y., Kato S., Bessho K., Matsumoto T., Kusakabe T., Sugiura Y. Tetrahedron Lett. 37:1996;7801.
26. 4), and evaporated to give tetramer 10 as a solid (1.15 g, 74%).
27. 1H NMR and mass spectrometry and showed purity of at least 90%. The isolated yields after HPLC purification ranged from ca. 10-30%.
28. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, 5th ed; Approved Standard (M7A5); National Committee for Clinical Laboratory Standards, Wayne, PA, 2000.
29. 7 cfu in 0.5 mL) and treated IV 1 and 3 h post infection with positive control, test compound, or vehicle alone. Survival of animals, the primary endpoint of this study, was monitored for five days. For further details, see ref 14.